bifeprunox

Bifeprunox is an investigational atypical antipsychotic drug developed for the treatment of schizophrenia, psychosis, and Parkinson's disease. It acts as a partial agonist at dopamine D2 receptors and as an agonist at serotonin 5-HT1A receptors. This dual mechanism is thought to stabilize dopaminergic activity in the brain by decreasing dopamine activity where it is excessive and increasing it where it is deficient. Bifeprunox was designed to offer efficacy against both positive and negative symptoms of schizophrenia with a lower risk of side effects such as weight gain, hyperprolactinemia, cardiotoxicity, or metabolic disturbances compared to other antipsychotics. Despite promising early clinical data showing efficacy and favorable tolerability, development was discontinued after phase III trials failed to demonstrate sufficient benefit for regulatory approval[1][2][3][4][5][6][9].

Other names

bifeprunoxDU-127090DU127090DU 127090